Form 4: Arcutis Biotherapeutics Executive VP Burnett Reports Stock Transactions

Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, Patrick Burnett, reports acquisition and disposal of common stock and stock options related to vesting of restricted stock units.

Summary

• Patrick Burnett, Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On February 28, 2025, Burnett acquired 38,000 shares and 17,000 shares of common stock through restricted stock units (RSUs) at $0.
• Also on February 28, 2025, Burnett acquired 99,000 and 43,000 stock options with an exercise price of $13.69.
• On March 3, 2025, Burnett sold 2,819 shares at a weighted average price of $13.0311 to cover tax withholding obligations related to vesting RSUs.
• On March 4, 2025, Burnett sold 954 shares at a weighted average price of $13.2841 to cover tax withholding obligations related to vesting RSUs.
• Following these transactions, Burnett directly owns 166,089 shares of common stock and 142,000 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation. There is no indication of unusual or concerning activity.

Positives

• The acquisition of RSUs and stock options indicates confidence in the company's future performance.

Negatives

• The sale of shares to cover tax obligations could be perceived negatively, although it's a common practice.

Risks

• The value of the stock options is dependent on the future stock price of Arcutis Biotherapeutics.
• Continued service to the Issuer is required for the vesting of RSUs and stock options.

Future Outlook

The reporting person will continue to vest in RSUs and stock options subject to continued service with the issuer.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into insider transactions. These transactions are typical for executives receiving equity-based compensation.

Comparison to Industry Standards

• Equity compensation is a standard practice in the biotechnology industry to align executive interests with shareholder value.
• Vesting schedules for RSUs and stock options are generally consistent with industry norms, typically ranging from three to five years.
• Sales of shares to cover tax obligations are a common occurrence among executives receiving equity compensation.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• The sales of shares to cover tax obligations may slightly increase selling pressure on the stock.

Key Dates